Company Overview and News

 
Mirvac makes high Calibre $125m sale

2018-08-31 theage.com.au
Property developer and investor Mirvac has raised $125.2 million in the sale of a 50 per cent stake in the Calibre industrial estate in Sydney's west to an associated Morgan Stanley-Mirvac fund.
MGR MRVGF

 
Mirvac makes high Calibre $125m sale

2018-08-31 smh.com.au
Property developer and investor Mirvac has raised $125.2 million in the sale of a 50 per cent stake in the Calibre industrial estate in Sydney's west to an associated Morgan Stanley-Mirvac fund.
MGR MRVGF

 
New 32-storey tower approved for Brisbane CBD

2018-06-07 smh.com.au
A proposed 32-storey tower which would occupy an entire block and significantly change Brisbane’s CBD skyline has been given the green light.
MGR MRVGF

21
Deals of the day-Mergers and acquisitions

2018-06-06 reuters
June 6 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:
NSU MGR IP PAH INPAP MRVGF PDPR DVN ATHN ENLC

5
Deals of the day-Mergers and acquisitions

2018-06-06 reuters
June 6 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1100 GMT on Wednesday:
MGR IP MRVGF INPAP PDPR DVN ENLC

40
Australia's Mirvac buys 50 pct stake in Sydney property from Blackstone fund

2018-06-06 reuters
(Reuters) - Australian diversified landlord and property developer Mirvac Group (MGR.AX) on Wednesday said it has used its pre-emptive right to buy a 50 percent stake in a Sydney property from a fund managed by Blackstone Group LP (BX.N).
BGX MGR MRVGF BGLF BX BGB

12
Case for gender diversity on boards will survive the post-AMP backlash

2018-05-12 theage.com.au
It was a sharply-worded question, read aloud almost two hours into the fractious and agonisingly drawn-out annual meeting of troubled wealth giant AMP.
MBL DSH FBU MGR MYGSF MYRSY FCREY MRVGF FRCEF OGFGY FSUGY MDBKY MYR MPL FSUMF FBU INCZY FMG OGFGF ICPVF IPL ORG

12
Case for gender diversity on boards will survive the post-AMP backlash

2018-05-12 smh.com.au
It was a sharply-worded question, read aloud almost two hours into the fractious and agonisingly drawn-out annual meeting of troubled wealth giant AMP.
MBL DSH FBU MGR MYGSF MYRSY FCREY MRVGF FRCEF OGFGY FSUGY MDBKY MYR MPL FSUMF FBU INCZY FMG OGFGF ICPVF IPL ORG

12
'The ship has sailed' - push back against on women on boards will fail

2018-05-11 theage.com.au
It was a sharply-worded question, read aloud almost two hours into the fractious and agonisingly drawn-out annual meeting of troubled wealth giant AMP.
MBL DSH FBU MGR MYGSF MYRSY FCREY MRVGF FRCEF OGFGY FSUGY MDBKY MYR MPL FSUMF FBU INCZY FMG OGFGF ICPVF IPL ORG

12
'The ship has sailed' - push back against on women on boards will fail

2018-05-11 smh.com.au
It was a sharply-worded question, read aloud almost two hours into the fractious and agonisingly drawn-out annual meeting of troubled wealth giant AMP.
MBL DSH FBU MGR MYGSF MYRSY FCREY MRVGF FRCEF OGFGY FSUGY MDBKY MYR MPL FSUMF FBU INCZY FMG OGFGF ICPVF IPL ORG

1
Reserve Bank to sell Melbourne headquarters

2018-04-10 theage.com.au
The Reserve Bank of Australia is set to offload a prime Collins Street building in Melbourne in a move that will boost government coffers by an estimated $110 million.
MBL MGR MRVGF

1
Reserve Bank to sell Melbourne headquarters

2018-04-10 smh.com.au
The Reserve Bank of Australia is set to offload a prime Collins Street building in Melbourne in a move that will boost government coffers by an estimated $110 million.
MBL MGR MRVGF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to ASX:MGR / MIRVAC GROUP on message board site Silicon Investor.

Mongolia Gold Resources Mongolia Gold Resources Mongolia Gold Resources LMGR - Light Management Group Inc LMGR - Light Management Group Inc LMGR - Light Management Group Inc
Overseas Filmgroup, Inc. OSFG Overseas Filmgroup, Inc. OSFG Overseas Filmgroup, Inc. OSFG MMGRD combo of synetic/medical manger MMGRD combo of synetic/medical manger MMGRD combo of synetic/medical manger
Medical Manager MMGR ( an EDS holding ?????) Medical Manager MMGR ( an EDS holding ?????) Medical Manager MMGR ( an EDS holding ?????) Technology Stocks SEPR MMGR GLC FONR Interesting NetArtcls Technology Stocks SEPR MMGR GLC FONR Interesting NetArtcls Technology Stocks SEPR MMGR GLC FONR Interesting NetArtcls
Magra MGRA Magra MGRA Magra MGRA